Updates are available Correction dated 2020-10-20

Article History

First Online: 3 August 2020

Change Date: 20 October 2020

Change Type: Correction

Change Details: The article Biologic Drug Quality Assurance to Optimize HER2+���Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3,

Declarations

:

: Not applicable

: Not applicable

: Gary H. Lyman, João Gonçalves, and Xavier Pivot have received consulting fees and/or speaking honoraria from Samsung Bioepis; João Gonçalves has received speaker honoraria and consulting fees from Amgen and Samsung Bioepis; Minji Seo is an employee of Samsung Bioepis. Diana Lüftner has no conflicts of interest that are directly relevant to the content of this article.

: Not applicable

: Not applicable

: Not applicable

: The authors acknowledge Weber Shandwick Hong Kong for editorial support in the preparation of this manuscript with funding from Samsung Bioepis.